Brachytherapy Gains Momentum With 12-Year Survival Data Released At AUA
This article was originally published in The Gray Sheet
Executive Summary
Favorable long-term efficacy data continue to fuel rapid growth in prostate cancer brachytherapy, which physicians predict will be the treatment of choice in 25% of cases in 2000.
You may also be interested in...
Bard Views GI, AAA Devices And Brachytherapy Seeds As Key Growth Drivers
Bard is hopeful that the Health Care Financing Administration will deem the firm's endoscopic suturing system for gastroesophageal reflux disease eligible for supplementary reimbursement under the agency's outpatient prospective payment system.
Uromed, Implant Sciences Join Prostate Cancer Brachytherapy Free-For-All
Uromed and Implant Sciences are the most recent entries into the rapidly growing market for prostate-brachytherapy seeds, estimated at $150 mil. in 1999.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.